Luminex Co. (NASDAQ:LMNX) Given Average Recommendation of “Hold” by Brokerages

Luminex Co. (NASDAQ:LMNX) has received a consensus rating of “Hold” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $25.67.

A number of research analysts recently weighed in on the stock. ValuEngine raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 17th. William Blair reissued a “market perform” rating on shares of Luminex in a report on Tuesday, May 7th. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, BidaskClub lowered shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, June 27th.

Shares of Luminex stock traded down $0.05 on Friday, hitting $19.84. 5,461 shares of the company traded hands, compared to its average volume of 263,986. The firm has a market cap of $901.80 million, a PE ratio of 41.33, a P/E/G ratio of 18.56 and a beta of 0.74. The company has a quick ratio of 2.70, a current ratio of 3.99 and a debt-to-equity ratio of 0.04. Luminex has a 52 week low of $19.73 and a 52 week high of $35.37. The company’s 50-day moving average price is $20.92.

Luminex (NASDAQ:LMNX) last released its quarterly earnings data on Monday, May 6th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.14). Luminex had a net margin of 2.55% and a return on equity of 1.62%. The company had revenue of $82.41 million for the quarter, compared to the consensus estimate of $83.10 million. During the same quarter in the previous year, the business earned $0.30 EPS. The company’s quarterly revenue was down .3% on a year-over-year basis. As a group, research analysts anticipate that Luminex will post 0.07 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Investors of record on Thursday, June 20th were issued a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend was Wednesday, June 19th. Luminex’s dividend payout ratio (DPR) is presently 50.00%.

Several hedge funds have recently bought and sold shares of LMNX. Oregon Public Employees Retirement Fund acquired a new position in shares of Luminex in the 4th quarter valued at $364,000. First Trust Advisors LP bought a new stake in Luminex during the 4th quarter worth about $1,940,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in Luminex during the 4th quarter worth about $100,000. Texas Permanent School Fund lifted its position in Luminex by 3.9% during the 4th quarter. Texas Permanent School Fund now owns 27,131 shares of the medical instruments supplier’s stock worth $627,000 after buying an additional 1,028 shares in the last quarter. Finally, Martingale Asset Management L P raised its holdings in shares of Luminex by 59.1% in the 4th quarter. Martingale Asset Management L P now owns 142,415 shares of the medical instruments supplier’s stock valued at $3,293,000 after purchasing an additional 52,905 shares during the period. 84.66% of the stock is owned by hedge funds and other institutional investors.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Further Reading: What is the Fibonacci sequence?

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with's FREE daily email newsletter.